title: Circulating CD147 predicts mortality in advanced hepatocellular carcinoma.
abstract: OBJECTIVE
  The glycoprotein CD147 has a role in tumor progression, is readily detectable in the circulation, and is abundantly expressed in hepatocellular carcinoma (HCC). Advanced HCC patients are a heterogeneous group with some individuals having dismal survival. The aim of this study was to examine circulating soluble CD147 levels as a prognostic marker in HCC patients.
  
  
  METHODS
  CD147 was measured in 277 patients (110 HCC, 115 chronic liver disease, and 52 non-liver disease). Clinical data included etiology, tumor progression, Barcelona Clinic Liver Cancer (BCLC) stage, and treatment response. Patients with HCC were stratified into two groups based upon the 75th percentile of CD147 levels (24 ng/mL).
  
  
  RESULTS
  CD147 in HCC correlated inversely with poor survival (P = 0.031). Increased CD147 predicted poor survival in BCLC stages C and D (P = 0.045), and CD147 levels >24 ng/mL predicted a significantly diminished 90-day and 180-day survival time (hazard ratio [HR] = 6.1; 95% confidence interval [CI]: 2.1-63.2; P = 0.0045 and HR = 2.8; 95% CI: 1.2-12.6; P = 0.028, respectively). In BCLC stage C, CD147 predicted prognosis; levels >24 ng/mL were associated with a median survival of 1.5 months compared with 6.5 months with CD147 levels ≤24 ng/mL (P = 0.03). CD147 also identified patients with a poor prognosis independent from treatment frequency, modality, and tumor size.
  
  
  CONCLUSIONS
  Circulating CD147 is an independent marker of survival in advanced HCC. CD147 requires further evaluation as a potential new prognostic measure in HCC to identify patients with advanced disease who have a poor prognosis.
authors: Centenary Institute of Cancer Medicine and Cell Biology, Camperdown, New South Wales, Australia.|Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.
authors: Aimei
authors: A
authors: Lee
authors: Department of Gastroenterology and Hepatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
authors: Anthony
authors: A
authors: Rode
authors: Department of Gastroenterology and Hepatology, Box Hill Hospital, Box Hill, Victoria, Australia.
authors: Amanda
authors: A
authors: Nicoll
authors: Centenary Institute of Cancer Medicine and Cell Biology, Camperdown, New South Wales, Australia.|Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.
authors: Annette E
authors: AE
authors: Maczurek
authors: Victorian Liver Transplant Unit and Department of Gastroenterology, Austin Hospital, Melbourne, Victoria, Australia.
authors: Lucy
authors: L
authors: Lim
authors: Department of Gastroenterology and Hepatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.
authors: Seok
authors: S
authors: Lim
authors: Victorian Liver Transplant Unit and Department of Gastroenterology, Austin Hospital, Melbourne, Victoria, Australia.
authors: Peter
authors: P
authors: Angus
authors: Department of Gastroenterology, Western Hospital, Footscray, Victoria, Australia.
authors: Ian
authors: I
authors: Kronborg
authors: Department of Gastroenterology, Western Hospital, Footscray, Victoria, Australia.
authors: Niranjan
authors: N
authors: Arachchi
authors: Melbourne EpiCentre, University of Melbourne and Melbourne Health, Parkville, Victoria, Australia.
authors: Alexandra
authors: A
authors: Gorelik
authors: Melbourne EpiCentre, University of Melbourne and Melbourne Health, Parkville, Victoria, Australia.
authors: Danny
authors: D
authors: Liew
authors: Centenary Institute of Cancer Medicine and Cell Biology, Camperdown, New South Wales, Australia.|Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.
authors: Fiona J
authors: FJ
authors: Warner
authors: Centenary Institute of Cancer Medicine and Cell Biology, Camperdown, New South Wales, Australia.|Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.|A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
authors: Geoffrey W
authors: GW
authors: McCaughan
authors: Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.|Department of Endocrinology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
authors: Susan V
authors: SV
authors: McLennan
authors: Centenary Institute of Cancer Medicine and Cell Biology, Camperdown, New South Wales, Australia.|Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.|A.W. Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.
authors: Nicholas A
authors: NA
authors: Shackel
mesh_terms: D000368:Aged; D051926:Basigin / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000401:mortality; D018450:Disease Progression; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
chemical_list: C497886:BSG protein, human; D014408:Biomarkers, Tumor; D051926:Basigin
keywords: CD147; biomarker; hepatocellular carcinoma; prognosis